Core Viewpoint - The article discusses the limitations of current cancer therapies based on secreted proteins and highlights a new research study that identifies potential immunotherapy targets through a cancer immunology data platform [2][3][12]. Group 1: Research Findings - The study developed a cancer immunology data platform called CIDE, which integrates 90 multi-omics datasets covering 8,575 tumor samples across 17 types of solid tumors [8][12]. - CIDE systematically identifies genes related to immunotherapy outcomes and has revealed secreted proteins such as AOAH, CR1L, COLQ, and ADAMTS7 as new immune checkpoint blockade (ICB) regulators [9][15]. - AOAH enhances immunotherapy through dual mechanisms: increasing T cell receptor (TCR) sensitivity to weak antigens and removing inhibitory lipids that suppress dendritic cell function [10][15]. Group 2: Implications for Cancer Treatment - The findings suggest that the identified secreted proteins could serve as precise targets for a new generation of immunotherapies, overcoming the limitations of traditional therapies like IL-2 and VEGF inhibitors, which have low response rates and unstable efficacy [17]. - AOAH's validation across multiple tumor models indicates its potential as a broad-spectrum immune enhancer [18]. Group 3: Future Directions - The research aims to expand the functional map of secreted proteins, particularly focusing on the 61% of previously unreported proteins related to cancer, to discover new molecules that regulate the immune microenvironment [20]. - There is a focus on targeting lipid-immune interactions based on AOAH-related lipid metabolism pathways for developing small molecule drugs or combination therapies [20]. - The study emphasizes the need for clinical translation of molecules like AOAH as biomarkers or therapeutic targets through preclinical and clinical trials [20].